NCT03032588View on ClinicalTrials.gov

A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

May 18, 2018

Study Completion Date

May 18, 2018

Conditions
Healthy
Interventions
BIOLOGICAL

sIPV

Participants will receive single dose (0.5 milliliter \[mL\]) of sIPV as a suspension for intramuscular injection on Day 1.

BIOLOGICAL

cIPV

Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.

Trial Locations (1)

9000

Center for Vaccinology (CEVAC), Ghent

All Listed Sponsors
lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT03032588 - A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults | Biotech Hunter | Biotech Hunter